Baseline Lymphopenia Predicts Survival in ICI-Naïve Solid Tumor Patients Receiving Immune Checkpoint Inhibitors: A Propensity-Matched Real-World Pan-Cancer Analysis

Ahmed Ismail, Nina Balanchivadze, George R. Simon, Yanis Boumber · 2026

Read Baseline Lymphopenia Predicts Survival in ICI-Naïve Solid Tumor Patients Receiving Immune Checkpoint Inhibitors: A Propensity-Matched Real-World Pan-Cancer Analysis by Ahmed Ismail, Nina Balanchivadze, George R. Simon, Yanis Boumber (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13297561.txt.

Description

Ahmed Ismail and colleagues ask whether a low lymphocyte count before immunotherapy marks cancer patients headed for worse outcomes, in a 2026 study of health records. Lymphocytes are the white cells that immune checkpoint drugs unleash against tumours. The team used a large United States record network and matched patients with low counts to similar patients with normal counts.

Patients starting treatment with low counts lived shorter lives across tumour types. They also needed more hospital care soon after starting and may have suffered more serious infections. Immune side effects, though, showed no clear rise. A cheap, routine blood test could thus flag patients who need closer watching and support during treatment.

Catalog record

CREATORAhmed Ismail, Nina Balanchivadze, George R. Simon, Yanis Boumber
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE53 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13297561

Browse the full library · About the Tower of Babel